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Inflammatory bowel disease (IBD) is a chronic and disrupted inflammation of the gastrointestinal tract. IBD have two main
conditions, Crohn’s disease and ulcerative colitis, and have been extensively investigated in recent years. Antibiotics derived from
salicylates, steroids, immunosuppressors, and anti-TNF therapy are part of the therapeutic arsenal for IBD. However, very often
patients stop responding to treatments over the time. In this context, searching for alternative agents is crucial for IBD clinical
management. Natural products derived from medicinal plants are an interesting therapeutic alternative, since several studies
have proven effective treatments in animal models of intestinal inflammation. Several naturally occurring compounds are potent
antioxidants, both as free radical scavengers and asmodulators of antioxidant enzymes expression and activity. A number of natural
compounds have also been proved to inhibit the release of proinflammatory cytokines, decreasing the activation of nuclear factor
𝜅B (NF-𝜅B), which is important to the inflammatory response in IBD. The alkaloids are substances of a very diverse class of plant
secondary metabolites; an extensive list of biological activities has been attributed to alkaloids, such as being anticholinergic,
antitumor, diuretic, antiviral, antihypertensive, antiulcer, analgesic, and anti-inflammatory. In the present work, studies on the
pharmacological activity of alkaloids in experimental models of IBD were reviewed.
1. Introduction
Inflammatory bowel disease (IBD) is a chronic inflammatory
disorder in the gastrointestinal tract and primarily includes
two forms, ulcerative colitis (UC) and Crohn’s disease (CD)
[1]. UC is characterized by an inflammatory response with
edema, ulceration and bleeding, and morphological changes
along with the intestine mucosae, involving infiltration of
polymorphonuclear cells (PMN), abscesses formation in
mucosal crypts, and glands distortion. These changes are
concentrated in the mucosa and restricted to the colon and
rectum [2]. CD can affect any portion of the gastrointestinal
tract, disturbing mainly the submucosa, but may be trans-
mural and exceed the serosa, creating fistulas [3]. Etiology of
IBD is complex and involves environmental factors, genetic
factors, and an exacerbated immune response to commensal
bacteria [4–6].
IBD was initially recognized as a health problem of
developed countries; however, in a recent review, Molodecky
and collaborators [7] have also reported increasing incidence
and prevalence of IBD in developing countries, probably due
to changes in lifestyles of these populations [8].
The therapy of IBD presents lack of effectiveness, high
costs, and numerous side effects [9, 10]. Although anti-
TNF𝛼 therapy revolutionized IBD clinical management, the
number of reports showing loss of response in patients
have been increasing. Moreover, almost one-third of IBD
cases have not improved after anti-TNF𝛼 therapy [11].
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 8528210, 24 pages
http://dx.doi.org/10.1155/2017/8528210
2 Evidence-Based Complementary and Alternative Medicine
Thus, the search for new alternative for the IBD therapy is
still sine qua non.
For a century, natural products have been in the vanguard
of drug discovery research, but, after the advent of automated
high throughput screening (HTS) programs, the use of nat-
ural products in drug discovery in pharmaceutical industry
declined [12]. However, natural products still continue to
contribute to the drug development for cancer, infectious
(bacterial, fungal, parasitic, and viral), immunological, car-
diovascular, neurological, inflammatory, and related diseases
[13, 14]. There is an increase in the number of IBD patients
using complementary herbal therapies andmany experimen-
tal studies and clinical trials present beneficial effect of vegetal
extracts, fractions, or compounds [15].
In this work, we made a review in the studies on the
effects of alkaloids, a class of plant compounds with sev-
eral biological activities reported, in experimental intestinal
inflammatory injury.
2. Alkaloids
The definition of the term alkaloid is not simple, but, in
general, alkaloids are a group of natural nitrogen-containing
basic compounds with low molecular weight, synthetized
from amino acids and biologically active [16]. Alkaloids are
a diverse group of compounds found in bacteria, fungi,
plants, and animals [17]. There are three types of alkaloids:
true alkaloids, protoalkaloids, and pseudoalkaloids. True
alkaloids have a heterocyclic ring with nitrogen, while, in
the protoalkaloids, the N atom derived from amino acids
is not part of heterocyclic ring. Pseudoalkaloids are not
originated from amino acids, including terpene-like, purine-
like, and steroid-like alkaloids. The major groups of alkaloids
are summarized in Figure 1.
The first alkaloids for medicinal use were isolated at the
beginning of 19th century, by Derosne (opium salt, nar-
cotine) and Sertu¨rner (principium somniferum, morphine).
The chemical identification of morphine was carried in
1923, by Robinson and Gulland [18, 19]. So far, there are
more than 20000 alkaloids identified and a number of them
have been placed an important role in clinical practice
[20]. They present numerous biological activities such as
being emetic, anticholinergic, antitumor, diuretic, sympa-
thomimetic, antiviral, antihypertensive, analgesic, antide-
pressant, muscle relaxant, anti-inflammatory, antimicrobial,
and antiulcer [21, 22]. The alkaloids have proton-accepting
nitrogen atom and one or more proton-donating amine
hydrogen atoms, which form hydrogen bonds with proteins,
enzymes, and receptors. Furthermore, they, generally, have
functional groups such as phenolic hydroxyl. The later might
explain the exceptional bioactivity of the alkaloids [17].
Several studies have been demonstrating the anti-
inflammatory activity of alkaloids, involving inhibition or
regulation of important inflammation mediators such as
NF-𝜅B, COX-2, and iNOS [23–29]. Souto et al. reviewed
published studies to evaluate the anti-inflammatory activity
of alkaloids and reported 40 of these compounds with
significant activity [30]. Antioxidant activity of alkaloids
have also been presented in different experimental models
or pathological conditions [31–35]. Based on the chemical
diversity of alkaloids and their biological activities previously
reported, these compounds emerge as potential agents for
intestinal inflammatory disorders.
3. Alkaloids and Experimental Colitis
This search was carried out on PubMed, Scopus, and Web
of Science database, using the terms “Inflammatory Bowel
Disease” OR “experimental colitis” OR “ulcerative colitis” OR
“Crohn’s Disease” OR “Colitis” AND “Alkaloid”. Publications
over the last decade were considered.
3.1. Nicotine: Dual Role on IBD. Nicotine is studied as the
main compound responsible for cigarette smoking properties
on intestinal mucosa [36]. Smoking has an opposite effect in
the two forms of IBD: while smoking increases the number
and the risk of developing relapses in CD, inUC, surprisingly,
the episodes of active disease are decreased [37, 38]. The
effect of nicotine on intestinal inflammation has been widely
studied in experimental assays [39–42] and clinical trials [43–
45] and there are several reviews on the effects of nicotine in
relation to IBD [46–49].
3.2. Plant Extracts andHerbal Formulation. Thesearch shows
some studies with plant extracts or herbal formulations,
rich in alkaloids, used in traditional Chinese and Ayurvedic
medicine as Amaranthus roxburghianus, Hangeshashinto,
Fructus Mume pill, Sangrovit, and Sophora alopecuroides.
Our search on alkaloid and IBD has led to several plant
extracts or herbal formulations commonly used in traditional
Chinese and Ayurvedic medicine, such as Hangeshashinto
(HST), Sophora alopecuroides, Fructus Mume pill (FMP),
Sangrovit and, and Amaranthus roxburghianus.
Kawashima and colleagues [50] evaluated a combination
of oriental medicinal plants, HST, in TNBS-induced colitis.
Wistar rats treated with HST for 5 days presented decreased
colon damage (macroscopic lesion score, ulcerative area, and
colon weight), reduced diarrhea, and increased body weight.
The authors also evaluated the effect of main constituents of
HST, berberine (BE), baicalin (BA), glycyrrhizin (GL), and
ginsenosides (GS) in the experimental TNBS colitis. These
components were given alone, in combination (BA + BE and
GL + GS), or in a total mixture (BA + BE + GL + GS).
The compounds given alone and the combination BA + BE
did not prevent colon injury, while GL + GS and the total
mixture ameliorated the intestinal inflammation.The authors
concluded that neither berberine nor baicalin is responsible
for HST anticolitis effect; thus, HST was suggested to prevent
or diminish the colitic phenotype due to the synergistic
combination of its components.
Effects of total alkaloids of Sophora alopecuroides (TASA)
were evaluated in TNBS-induced colitis in rats, by Chen and
Deng [51]. TASA ameliorated histological damage, increased
SOD activity, and decreased MDA levels, as well as NO and
MPO activity. In a study from Zhou and colleagues [52],
employing the same experimental model, the oral treatment
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Figure 1: Main alkaloids groups: True Alkaloids (a), Protolakaloids (b) and Pseudoalkaloids (c), precursors, and skeleton structures. Adapted
from Aniszewski, 2007 [18]. Chemical structures were getting in PubChem database.
with TASA decreased damage scores, maybe due to the
upregulation of CD4+ CD25+ regulatory T cells (Tregs) and
anti-inflammatory cytokine IL-10.
The effect of TASA on DSS-induced intestinal inflam-
mation in mice has also been investigated. In this model,
TASA inhibited acute inflammation in the gut by inhibiting
the secretion of IL-1𝛽 and promoting the release of anti-
inflammatory cytokine IL-4 [53]. Zhao et al. [54] assayed
TASA treatment on DSS-induced chronic intestine injury.
Chronically, TASA exhibited protective effects on DSS colitis
inhibiting secretory immunoglobulin A and haptoglobin
release; likewise, the intercellular adhesion molecule 1
(ICAM-1) gene expression and p65 recruitment to the ICAM-
1 gene promoter were also found inhibited, suggesting that
TASA might protect the intestine from injury by inhibiting
NF-𝜅B activation.
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FMP is a combination of ten Chinese herbs that has been
used for a long time in traditional Chinese medicine for
the treatment of diarrhea and dysentery; indeed, the State
Food and Drug Administration of China approved its use
for the management of gastrointestinal disorders. The effect
of FMP was evaluated on TNBS-induced colitis in Sprague-
Dawley rats. Remarkable results include reduced ulcer area,
colon weight/length ratio, diarrhea, colonic MPO activity,
INF-𝛾 levels, gram −/gram + bacteria relation, and increased
IL-4 levels [55]. The authors suggested that these effects
may be related to the alkaloids aconitine and berberine.
In another study, Zhang and colleagues [56] reported the
synergistic activity of three alkaloids from FMP: berberine,
hypaconitine, and skimmianine on TNBS-induced colitis in
rats. Berberine ameliorated intestinal injury and diminished
TNF-𝛼 levels and NF-𝜅B expression in colon but had no
effect on abdominal pain (in acetic acid-induced writhing)
nor gastrointestinal transit. Althoughhypaconitine and skim-
mianine did not exhibit anti-inflammatory activity on TNBS-
induced colitis, the treatment with the combination of the
three alkaloids ameliorated the colonic injury. The authors
suggest that berberine exerted mainly anti-inflammatory
activity, while hypaconitine possesses analgesic effect and
skimmianine antidiarrheal properties.
Vrublova and colleagues [57] assayed the Sangrovit (rich
in isoquinoline alkaloids) feeding supplementation in DSS-
induced colitis in Wistar rats. Sangrovit is used as appetizer
supplement in livestock feed. Sangrovit ameliorated histolog-
ical damage score, decreasing COX-2 expression and colonic
MPO activity.The alkaloids sanguinarine, dihydrosanguinar-
ine, chelerythrine, and dihydrochelerythrine were found in
the colon of Sangrovit-treated animals, suggesting a direct
effect of these compounds in the colonic mucosae.
Iablokov and colleagues [58] evaluated the effects of
potatoes glycoalkaloids on IL-10 knockout mice (genetic
predisposition to develop colitis) and DSS treated mice.
Their data show increased INF-𝛾 levels in ileum of IL-10
knockout mice and increased intestinal permeability and
INF-𝛾, IL-17, and TNF-𝛼 levels in DSS colitis mice. As
a consequence, deleterious effects of glycoalkaloids were
reported. The authors attributed such effects, mainly, to the
compounds 𝛼-chaconine and 𝛼-solanine. The glycoalkaloids
concentration can raise in about threefold in fried potatoes
which has been shown to aggravate intestinal inflammation.
Nirmal and collaborators [59] analyzed the effect of
Amaranthus roxburghianus root extract in combination with
piperine on acid acetic-induced colonic injury in mice. The
treatment with A. roxburghianus decreased histopathological
damage, MPO activity, and MDA levels and major levels of
reduced GSH compared to control (5% acetic acid). Inter-
estingly, the combination with piperine improved the effects
of the extract, similarly to those observed for prednisolone-
treated animals while piperine itself had no effect.
In a recent publication, Bribi and colleagues [60] reported
the protective effect of total alkaloids of Fumaria capreolata
(AFC) on DNBS-induced colitis in mice. AFC treatment
decreased the body weight loss, colon weight/length ratio,
andmicroscopic score. AFC inhibited the increase of TNF-𝛼,
IL-1𝛽, Il-6, IL-12, iNOS, ICAM-1, and MMP-9 and prevented
the downregulation of MUC-2 mRNA expression in the
colon. In LPS-stimulatedCMT93 cells, AFCprevented upreg-
ulation of of ICAM-1, TNF-𝛼, and IL-6 mRNA expression
and the release of TNF-𝛼 and IL-6. In addition, ACF has also
prevented the downregulation of ofMUC-2 and ZO-1 expres-
sion in LPS-stimulatedCMT93 cells. Stylopine, coptisine, and
protropine were identified as major compounds in AFC.
3.3. Isolated Alkaloids. We found 32 alkaloids with activity
assessed in experimental models that induced the disrupt of
the epithelial barrier (DSS, acetic acid, or mustard oil) or
that involved hapten-induced hypersensitive reactions in the
intestinal inflammation (TNBS), mainly in mice.
In accordance with structural forms, the cited alkaloids
are classified in diterpenoid alkaloids (14-O-acetylneoline,
14-O-veratroylpseudaconine, and hypaconitine), indole alka-
loids (fumigaclavine C and isatin), indolonaphthyridine alka-
loids (nigakinone), indoloquinazoline alkaloids (tryptan-
thin), isoquinoline alkaloids (berberine, boldine, cavidine,
coptisine derivatives, EM012, papaverine, sanguinarine, sino-
menine, tetrahydrocoptisine, and tetrandrine), phenan-
throindolizidine alkaloids (NK-007 and W-8), piperidine
alkaloids (piperine), purine alkaloids (caffeine), quinoline
alkaloids (skimmianine), and quinolizidine alkaloids (mat-
rine, oxymatrine, sophocarpine, and sophoridine). The
effects of these alkaloids on experimental colitis are summa-
rized in Table 1. Berberine, sinomenine, and piperine effects
on experimental colitis were assessed in two or more
manuscripts, as detailed hereafter.
Berberine has been the wieldiest studied alkaloid with
pharmacological activity in intestinal inflammatory models.
It is one of the main substances of Berberis sp. [95]. It
is also isolated from Hydrastis, Coptis, and Phellodendron
species [96]. The effect of berberine in colitis was evaluated
in DSS and TNBS-induced colitis in mice and rats. This
alkaloid ameliorates colon injury and inhibits the increase of
inflammatory mediators and oxidative damage, as described
in Table 1.
The treatment with berberine was used as reference drug
for Berberis vulgaris fruit extract (BFE) treatment during
the evaluation of its effects on acetic acid-induced colitis
[65]. Both oral BFE and enema treatment were effective in
diminishing the macroscopic and histopathological damage.
As BFE is nearly disproved of berberine alkaloid, the authors
attributed the effect to other components, such as antho-
cyanins. Kawashima and collaborators [50] reported no sig-
nificant effect of berberine (3.75 or 6.5mg⋅kg−1) treatment in
TNBS-induced colitis.This result is probably due to the doses
used, while the protective effect of berberine in experimental
colitis was observed with doses of 10–100mg⋅kg−1 [64, 66, 67,
69].
The addition of berberine (20mg⋅kg−1) to 5-ASA treat-
ment (200mg⋅kg−1) decreased disease severity of colitis
induced by DSS in mice. 5-ASA in combination with
berberine decreased the disease activity index (DAI) and
histological injury, inhibited COX-2, TNF-𝛼, IL-12b, and
IL-23 expression in colon tissue, and inhibited NF-𝜅B and
JAK activation. Moreover, the combination of 5-ASA and
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berberine did not produce any deleterious effects in mice.
The authors suggest that the combination is promising to UC
therapy.
Berberine is an isoquinoline quaternary alkaloid and
presents therapeutic properties, as antimicrobial, antidia-
betic, anticancer, and anti-inflammatory, and has pharma-
cological activity in gastroenteritis, abdominal pain, and
diarrhea [28, 31, 97]. Berberine also improves intestinal
epithelial tight junction integrity, as presented by Gu et al.
[98]. This study proposes reduced epithelial gut permeability
as a possiblemechanismof antidiarrheic activity of berberine.
DiGuilio and colleagues [99] tested berberine treatment,
in vitro, using CACO-2 cells barrier leaking induced by
cytokines (TNF-𝛼, IL-1𝛽, and INF-𝛾) or hydrogen peroxide.
Berberine enhanced basal CACO-2 barrier integrity and also
decreased cytokine-induced injury in epithelial barrier func-
tion, suggesting that this phenomenon might also contribute
to the role of berberine on experimental model of colitis.
The alkaloid oxymatrine activity in experimental colitis
was reported in four articles [79–81, 83]. The treatment with
oxymatrine improves TNBS and DSS-induced colitis. The
protective effect of oxymatrine was also evaluated in intesti-
nal injury induced by ischemia and reperfusion. The authors
reported decreased apoptosis index, intestinal lipid peroxi-
dation, serum TNF-𝛼 levels, phosphorylated p38 mitogen-
activated protein kinase (MAPK), and Fas/FasL expression
[100].
Sinomenine activity in experimental colitis was reported
in two manuscripts [88, 89]. This alkaloid inhibits the gener-
ation of inflammatory mediators in TNBS-induced colitis in
mice. In experimental model of colitis, sinomenine has been
suggested to downregulate microRNA 155 (MiR-155), the
transcription factor c-Maf, and the cytokines TNF-𝛼 and
IFN-𝛾. Sinomenine has also demonstrated analgesic activity
on neuropathic and inflammatory pain models [101], sup-
pressive effect on colon carcinoma cell growth [102, 103], and
anti-inflammatory activity [104].
Li and collaborators [105] employed the alkaloid piperine
to ameliorate curcumin absorption and pharmacological
activity. Piperine and curcumin were encapsulated in a nano-
formulation, called self-microemulsifying drug delivery sys-
tem (CUR-PIP-SMEDDS). The system CUR-PIP-SMEDDS
increased the drug stability and the dissolution of curcumin
at the colon site (in vitro) and showed therapeutic effects in
DSS-induced colitis in mice. CUR-PIP-SMEDDS decreased
DAI, histopathological lesions, MPO activity, MDA content,
TNF-𝛼, and IL-6 levels in colonic tissue of mice.
In a study from Hu et al. [85], the evaluation of the
mechanisms of action of piperine on DSS-induced colitis
allowed the development of siRNA-mediated knockdown of
PXR in mouse colons and also indicated a role of PXR in
protecting colonic mucosae. Piperine treatment prevented
bodyweight loss, diarrhea, histological injury, and the expres-
sion of inflammatory mediators on DSS-induced colitis in
mice. When the PXR was downregulated, the DSS injury was
exacerbated and piperine protection against DSS colitis was
inhibited.
We found two studies with comparative analysis of
several alkaloids in experimental colitis. Wangchuk et al.
[62] isolated five diterpenoids alkaloids (pseudaconitine,
14-veratroylpseudaconine, 14-O-acetylneoline, neoline, and
senbusine A) of Aconitum laciniatum, a species of aconites of
polyherbal formulations in Bhutanese Traditional Medicine,
for inflammatory conditions. In this work, the authors
reported the evaluation of 14-veratroylpseudaconine and
14-O-acetylneoline in TNBS-induced colitis in mice. The
compound 14-veratroylpseudaconine exacerbated the TNBS-
induced damage, while 14-O-acetylneoline ameliorated some
signals of injury and inhibited the INF-𝛾 release. In the
manuscript of Zhang et al. [61], thirty synthesized coptisine
derivatives were found to activate the in vitro transcription
of x-box-binding protein 1 (XBP1). The dihydrocoptisines
were demonstrated to be much more active antiulcerative
colitis agents than quaternary coptisines and tetrahydro-
coptisines, by in vitro XBP1 transcriptional activity assays
and animal experiments (DSS-induced colitis). The authors
also demonstrated that reductive states and the substitution
patterns of the dihydrocoptisines are critical for their efficacy;
unsubstituted dihydrocoptisine exhibited more significant
efficacy in mice colitis than dihydrocoptisines substituted at
the C-8 or C-13 position.
4. Discussion
In the present search, alkaloids of different groups showed
protective activity in experimental colitis, involving distinct
mechanisms. Some alkaloids did not present significant
effects in colitis, whereas others, as potatoes glycoalkaloids,
exhibited deleterious action in IBD. The majority of the
alkaloids studied in experimental colitis were isolated from
herbal formulations and plant preparations used in tradi-
tional eastern medicine. The evaluation of these extracts in
experimental colitis showed their significant and beneficial
activity. The latter isolation and study of the components of
the effective extract identified some alkaloid with potential
activity in IBD. Among them, the berberine was the most
reported and the most cited in a review of alkaloid anti-
inflammatory activity [30]. This manuscript related 40 alka-
loids to active effects in different models of inflammation.
IBD therapy includes aminosalicylates, corticosteroids,
immunosuppressive agents, and biological agents. Amino-
sacicylates and corticosterois do not provide long-term clin-
ical response and mucosal healing and immunosuppressors
do not induce remission [106]. The anti-TNF-𝛼 drugs inflix-
imab and adalimumab improved IBD therapy. They have
been shown to induce clinical and endoscopic remission in
bothCDandUC, to diminish exacerbations and surgery rates
[107]. However, one-third of IBD patients are unresponsive
to TNF-𝛼 antibodies and another third of patients become
nonresponsive after a time of treatment. Efficacious treatment
options for these patients are imperative [108].
Natural products can be a source of immune modulators
antioxidants and anti-inflammatory substances [97, 109–111].
The berberine decreased colonic inflammation in UC and
CD experimental models and inhibited cytokines release
(TNF-𝛼, IL-1𝛽, IL-6, IL-12, and IL17). This effect can be
promising to IBD therapy, but there are no clinical studies
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related to berberine in IBD. This isoquinoline alkaloid has
been evaluated in different clinical trial studies and is showed
to decrease symptoms of irritable bowel syndrome [112],
nonalcoholic fatty liver disease [113], and acute coronary
syndrome inflammation [114] without any side effects related
to berberine treatment.
The combination of therapeutic drugs and alkaloids
may be an approach of induction of remission, with fewer
collateral effects. A minor dose of 5-ASA showed protective
effect in mice DSS colitis, in a combination with berberine
[115]. Abdel-Daim and collaborators highlighted the role of
natural products in ameliorating collateral effects of standard
drugs [116]. However, it is important to regard alkaloids
toxicity and safety to human use.
The study of alkaloid properties in IBD may contribute
to the development of new drugs. Considering the variety
of structures and the biological effects of alkaloids, anti-
inflammatory and antioxidant activity reported, and the
small number of published articles, there is still much to be
explored in this chemical class in IBD.
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